IIT-B startup ImmunoACT’s “affordable” blood cancer therapy gets regulatory approval – a first for India’s CAR-T cell therapy
An IIT Bombay incubated company, ImmunoACT, has been granted approval by Indian drug regulator Central Drugs Standard Control Organization (CDSCO) for its CAR-T cell therapy NexCAR19. According to an ET …